Correction {#Sec1}
==========

Following publication of the original article \[[@CR1]\], we have been alerted to errors in Figs. [2](#Fig1){ref-type="fig"} and [8](#Fig2){ref-type="fig"}. In Fig. [2b](#Fig1){ref-type="fig"}, the GAPDH loading control for Hec1A cells is shown twice in error (in Fig. [2b](#Fig1){ref-type="fig"} and Fig. [2c](#Fig1){ref-type="fig"}). In Fig. [8](#Fig2){ref-type="fig"}, in testis case 1 (first column) the MAGE-A4 staining panel was repeated and also appears as the NY-ESO-1 staining panel in error. The corrected versions of Fig. [2](#Fig1){ref-type="fig"} and Fig. [8](#Fig2){ref-type="fig"} are shown below. We apologize for this inconvenience.Fig. 2Regulation of L1CAM expression by epigenetic mechanisms. (**a**) RT-PCR analysis of cells treated for 5 days with the indicated concentration of 5-AzaC, TSA or both compounds. DMSO was used as a mock control. Cells were lysed and mRNA was isolated and transcribed into cDNA. β-actin served as internal standard. (**b**) Cells were treated as described above and cell lysates were prepared for Western blot analysis. MAb L1-11A was used as a primary antibody followed by peroxidase conjugated Goat anti mouse IgG and ECL detection. (**c**) TSA and VA up-regulate L1CAM expression. Cells were treated and analyzed as described in (**b**)Fig. 8IHC analysis of testis and EC tissues. Expression of NY-ESO-1 and MAGE-A4 but absence of L1CAM in normal human testis tissue. Conversely, L1CAM is expressed in type II EC but NY-ESO-1 and MAGE-A4 are undetectable. Note that a representative case of *n* = 5 is shown. Sequential tissue sections were analysed by IHC
